Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

Sparks, David S., Morris, Bradley, Xu, Wen, Fulton, Jessica, Atkinson, Victoria, Meade, Brian and Lutton, Nicholas (2015) Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. International Surgery, 100 1: 21-28. doi:10.9738/INTSURG-D-14-00089.1


Author Sparks, David S.
Morris, Bradley
Xu, Wen
Fulton, Jessica
Atkinson, Victoria
Meade, Brian
Lutton, Nicholas
Title Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix
Journal name International Surgery   Check publisher's open access policy
ISSN 0020-8868
Publication date 2015-01
Sub-type Article (original research)
DOI 10.9738/INTSURG-D-14-00089.1
Volume 100
Issue 1
Start page 21
End page 28
Total pages 8
Place of publication Chicago, IL, United States
Publisher International College of Surgeons
Collection year 2016
Language eng
Formatted abstract
Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a radical but effective treatment option for select peritoneal malignancies. We sought to determine our early experience with this method for peritoneal carcinomatosis secondary to mucinous adenocarcinomas of appendiceal origin. As such, we performed a retrospective clinical study of 30 consecutive patients undergoing CRS with planned HIPEC at the Princess Alexandra Hospital, between June 2009 to December 2012, with mucinous adenocarcinomas of the appendix. CRS was performed in 30 patients, 13 received HIPEC intraoperatively and 17 received early postoperative intra-peritoneal chemotherapy (EPIC) in addition. Mean age was 52.3 years and median hospital stay was 26 days (range 12-190 days). Peritoneal cancer index scores were 0-10 in 6.7% of patients, 11-20 in 20% of patients and > 20 in 73.3% of patients. Complete cytoreduction was achieved overall in 21 patients. In total, 106 complications were observed in 28 patients. Ten were grade 3-A, five were grade 3-B and one grade-5 secondary to a fatal PE on day 97. In patients who received HIPEC, there was no difference in disease-free survival (P = 0.098) or overall survival (P = 0.645) between those who received EPIC versus those who did not. This study demonstrates that satisfactory outcomes with regards to morbidity and survival can be achieved with CRS and HIPEC, at a single-centre institution with growing expertise in the technique. Our results are comparable with outcomes previously described in the international literature.
Keyword Pseudomyxoma peritonei
Cytoreductive surgery
Heated intraperitoneal chemotherapy
Early postoperative intraperitoneal chemotherapy
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 01 Mar 2015, 00:19:54 EST by System User on behalf of Scholarly Communication and Digitisation Service